FibroBiologics Stock (NASDAQ:FBLG)
Previous Close
$0.66
52W Range
$0.58 - $5.54
50D Avg
$0.75
200D Avg
$1.57
Market Cap
$28.01M
Avg Vol (3M)
$366.86K
Beta
-0.77
Div Yield
-
FBLG Company Profile
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.